HER2 cancer cells can develop resistance to trastuzumab through either interference with the binding of trastuzumab to the HER2 receptor, increased activation of downstream signaling pathways of HER2, activation of alternative signaling pathways, or the inability to initiate an immune-mediated mechanism for destroying tumor cells [38]. Here, ERBB2 is linked to neoplasm.